Ascendis Pharma announced that the U.S. Food & Drug Administration has issued a complete response letter for the TransCon PTH New Drug Application for the treatment of adults with hypoparathyroidism. In the letter, the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product. The FDA did not express concern about the clinical data submitted as part of the NDA package and no new preclinical studies, or Phase 3 clinical trials to evaluate safety or efficacy, were requested in the letter. Ascendis will request a Type A meeting with the FDA as soon as possible to agree on the best path forward. The company said, "As recently announced, 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and the U.S. Expanded Access Program continues to enroll new patients. In the clinical trials, TransCon PTH has been generally well tolerated, with no discontinuations related to study drug. We anticipate a European Commission decision on our MAA during the fourth quarter of 2023. If approved, we are planning our first EU launch in Germany in early 2024. In addition, we expect to enroll the first patient in a German early access program, if approved, during the second quarter of 2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Blasts Up despite FDA Troubles
- Ascendis Pharma price target raised to $152 from $142 at Cantor Fitzgerald
- Ascendis Pharma Reports First Quarter 2023 Financial Results
- Is ASND a Buy, Before Earnings?
- Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27